Multiple myeloma remains a challenging blood cancer because it often returns despite initial treatment. Many patients experience several rounds of therapy before their disease becomes resistant to commonly used medicines such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. For these patients, CAR-T cell therapy has opened a new treatment pathway by using the body’s own immune cells to recognize and destroy myeloma cells.
China has become one of the world’s leading centers for CAR-T innovation. Alongside approved BCMA-targeted CAR-T products, patients may also have access to next-generation therapies through clinical studies conducted at leading hematology hospitals. International patients increasingly choose China not only for advanced treatment options but also for the experience of physicians who have managed thousands of CAR-T cases.
Whether you are exploring treatment after relapse or looking for alternatives when standard therapies are no longer effective, our team can help you understand your options and connect you with experienced CAR-T specialists in China.
Patient video – multiple myleoma treatment
After multiple treatments failed, Thanyaphati traveled to China for CAR-T therapy for multiple myeloma. Following the infusion, the patient showed a strong clinical response with improved lab results. The experience was marked by professional care, advanced treatment, and supportive coordination throughout.
Why multiple myeloma remains difficult to cure
Unlike many cancers that can sometimes be completely removed by surgery, multiple myeloma develops throughout the bone marrow and involves abnormal plasma cells that can survive despite intensive treatment. Modern therapies have significantly improved survival, yet the disease often follows a pattern of remission followed by relapse.
Each relapse may become more difficult to treat as cancer cells develop resistance to previous medications. This is why many patients eventually require newer therapies that work through different biological mechanisms.
CAR-T cell therapy represents one of the most important advances because it is designed to target cancer cells directly instead of relying solely on traditional chemotherapy or continuous drug treatment.
How CAR-T cell therapy works against multiple myeloma
CAR-T cell therapy begins with collecting a patient’s own T cells through a blood collection procedure called leukapheresis. These immune cells are then genetically engineered in a specialized laboratory to recognize proteins found on myeloma cells, most commonly BCMA (B-cell maturation antigen).
Once the modified cells are returned to the patient’s bloodstream, they multiply and actively search for cancer cells carrying the target antigen. Unlike conventional medicines that gradually lose effectiveness, CAR-T cells may continue recognizing and attacking cancer cells after infusion, contributing to deep and sometimes long-lasting responses.
Researchers in China are also developing CAR-T therapies targeting GPRC5D and dual-antigen approaches designed to overcome treatment resistance and reduce the risk of relapse.
Why CAR-T therapy is transforming multiple myeloma treatment
For many years, treatment options became increasingly limited after several lines of therapy had failed. CAR-T therapy has changed this outlook by producing response rates that were previously difficult to achieve in heavily pretreated patients.
Clinical studies have shown that many patients experience rapid reductions in disease burden, with a substantial proportion achieving complete remission or minimal residual disease (MRD) negativity. While outcomes vary from person to person, these results have established CAR-T therapy as one of the most promising treatments for relapsed and refractory multiple myeloma.
Unlike maintenance therapies that require continuous medication, CAR-T treatment is generally administered as a single infusion after cell manufacturing, although careful monitoring remains essential during recovery.
Approved CAR-T therapies available in China
China has approved several CAR-T products for hematologic malignancies, including BCMA-directed therapies for multiple myeloma. These products have been evaluated through large clinical studies involving patients who had previously exhausted multiple treatment options.
One of the most important approved therapies is Fucaso (Equecabtagene Autoleucel), a BCMA-targeted CAR-T product that demonstrated high overall response rates and durable disease control in clinical trials.
China’s rapidly expanding regulatory environment also supports continued development of next-generation CAR-T products designed to improve treatment durability, shorten manufacturing time, and address resistance following previous therapies.
Get information of CAR-T cell therapy for multiple myeloma in China
CAR-T research in China continues to evolve
China has become one of the most active countries in CAR-T research, conducting hundreds of investigator-initiated and industry-sponsored studies across academic medical centers.
Current areas of research include:
- Dual-target CAR-T therapies
- BCMA and GPRC5D combination targeting
- Earlier use of CAR-T therapy
- Faster manufacturing technologies
- Strategies to reduce relapse
- Combination treatment with transplantation or novel immunotherapies
This active research environment provides eligible patients with access to innovative treatment approaches that may not yet be widely available elsewhere.
Who may benefit from CAR-T therapy?
CAR-T therapy is not suitable for every patient with multiple myeloma. Treatment decisions depend on several medical factors, including previous therapies, disease status, organ function, and overall health.
Patients who may be considered include those with:
- Relapsed multiple myeloma
- Disease resistant to standard treatment
- Failure after multiple treatment lines
- Relapse following stem cell transplantation
- Triple-class exposed or triple-class refractory disease
- Adequate physical condition to undergo treatment
Each patient undergoes an individualized evaluation before treatment recommendations are made.
What international patients can expect
Receiving CAR-T therapy involves careful planning before, during, and after treatment. Our international patient program is designed to simplify this process by coordinating medical reviews, physician consultations, travel arrangements, hospital admission, and follow-up support.
A typical treatment journey includes:
- Medical record review
- Expert opinion from a CAR-T specialist
- Treatment planning
- Travel preparation
- Leukapheresis
- CAR-T cell manufacturing
- Lymphodepletion chemotherapy
- CAR-T infusion
- Inpatient monitoring
- Follow-up assessment before returning home
Throughout the process, our multilingual coordinators assist patients and families with communication, logistics, and treatment scheduling.
Why many international patients choose China
China has developed one of the world’s largest CAR-T treatment ecosystems, bringing together academic hospitals, biotechnology companies, and experienced clinical teams.
Access to CAR-T cell therapy remains limited in many countries due to high costs, regulatory restrictions, or long waiting times. For patients who are unable to receive timely treatment locally, traveling abroad becomes a practical consideration.
Choosing to travel to China and get CAR-T therapy for multiple myeloma allows patients to access advanced treatment options more quickly. China has developed a strong ecosystem for cellular therapies, with experienced medical teams, modern facilities, and structured pathways for international patients. From initial consultation to post-treatment follow-up, services are designed to support patients and their families throughout the journey.
Patients choose China for several reasons:
- Access to approved CAR-T products
- Opportunities to participate in clinical trials
- Physicians experienced in complex hematologic cancers
- Advanced laboratory and manufacturing capabilities
- Comprehensive medical services for international patients
- Integrated treatment planning through multidisciplinary teams
Rather than focusing on a single therapy, many hospitals evaluate each patient comprehensively and recommend the most appropriate treatment strategy based on individual disease characteristics.
Cost of CAR-T cell therapy for multiple myeloma in China
CAR-T cell therapy for multiple myeloma in China is significantly more affordable than in Western countries, with total treatment costs roughly one-third of the price in the United States. For international patients, the overall expenses including medical services remain substantially lower, making China an increasingly attractive destination for CAR-T treatment.
This cost advantage stems from several factors: domestic CAR-T products are priced to align with local market conditions, the use of locally manufactured materials (such as viral vectors) reduces production expenses, and government-led initiatives prioritize treatment accessibility through commercial insurance and supplementary coverage schemes. Emerging innovations like off-the-shelf CAR-T and automated manufacturing platforms are expected to further drive costs down, expanding access for both domestic and international patients.
Where is CAR-T cell therapy for multiple myeloma available?
The Institute of Hematology & Blood Diseases Hospital (IHCAMS) is China’s top-ranked hematology specialty hospital for 14 consecutive years. As the National Clinical Research Center for Blood Diseases, IHCAMS leads the nation in clinical trials for hematological malignancies, conducting more than twice the number of trials as any other center in China. Our center leverages this unparalleled expertise and world-class research infrastructure to drive innovation in multiple myeloma cellular therapy.
Get medical evaluation from an expert in IHCAMS
Life after CAR-T therapy
Recovery continues after hospital discharge. Regular blood tests, bone marrow evaluations, and imaging studies help physicians assess treatment response and identify any delayed complications.
Some patients experience prolonged remission and return to normal daily activities, while others may require additional therapies if the disease eventually returns. Long-term follow-up remains an important part of care, allowing physicians to monitor recovery and recommend further treatment when necessary.
For international patients, our team coordinates communication between Chinese specialists and local healthcare providers to support continued care after returning home.
Is CAR-T cell therapy for multiple myloma effective?
Multiple myeloma is a type of cancer that arises from plasma cells, which are responsible for producing antibodies. In this condition, abnormal plasma cells accumulate in the bone marrow, leading to issues such as anemia, bone damage, kidney problems, and weakened immune function. This cancer disrupts normal blood production and can severely affect overall health.
Traditional treatments for multiple myeloma face several challenges, including limited efficacy, as many patients experience relapse and resistance to therapy over time. Severe side effects from chemotherapy and other treatments can significantly impact quality of life, and complex treatment regimens can hinder adherence, highlighting the need for innovative approaches like CAR T-cell therapy.
CAR-T cell therapy has emerged as one of the most promising treatment options for patients with relapsed or refractory multiple myeloma. By genetically modifying a patient’s own T cells to target specific antigens such as BCMA (B-cell maturation antigen), CAR-T therapy can directly attack myeloma cells with high precision.
Clinical studies and real-world outcomes have shown high response rates, including deep and durable remissions in patients who have already undergone multiple prior lines of treatment. For many patients, CAR-T cell therapy for MM in China offers access to advanced products and experienced treatment teams, making it a compelling option when standard therapies are no longer effective.
Frequently Asked Questions
CAR-T therapy is an advanced form of immunotherapy where a patient’s own T cells are collected and genetically modified in a laboratory. By inserting a gene that encodes a Chimeric Antigen Receptor (CAR), the T cells are essentially “reprogrammed” to recognize and target specific cancer cells—much like equipping them with a GPS to find and attack tumors, particularly those found in lymphomas and multiple myeloma. This process is referred to as CAR-T cell therapy.
The high cost of CAR-T therapy primarily stems from its personalized nature. It’s not an off-the-shelf drug; rather, it’s tailor-made for each individual patient. The process begins with apheresis to extract T cells from the patient’s blood. These cells are then genetically engineered and expanded in a highly controlled lab environment to create the final CAR-T product. This complex and labor-intensive process takes time, requires specialized facilities, and must be customized for each patient—factors that contribute significantly to its high price.
Studies show that earlier use of CAR-T can significantly improve survival and quality of life. Delaying treatment may mean missing the best chance for effective therapy.
Multiple myeloma is incurable and often relapses after initial success. With each relapse, treatment becomes less effective. After three lines of therapy, the chance of full remission is below 1%, and average survival drops to about 14.5 months.
For patients who don’t respond to multiple treatments, CAR-T may be the only option to extend life. Chinese guidelines now recommend its use after third-line treatment failure.
CAR-T cell therapies for multiple myeloma now include two approved products in China and two another in other countries. A key distinction lies in their source: CAR-T products in other countries use animal-derived antibodies, while the two CAR-T cell therapies in China are based on fully human antibodies.
Human-derived CAR-T therapies are better matched to the human immune system. They tend to cause fewer side effects after infusion and offer more sustained activity in the body. Because of this, they are often considered safer and more effective overall.
CAR-T therapy directly attacks tumor cells by damaging their membranes, making it highly effective even for high-risk myeloma. Unlike traditional treatments requiring multiple cycles, CAR-T is a one-time infusion with long-lasting effects—offering patients a simpler and potentially more effective option.
CAR-T therapy was first applied in treating leukemia. Fortunately, CAR-T treatments targeting multiple myeloma—especially those aimed at the BCMA (B-cell maturation antigen) target—have shown even higher effectiveness compared to CAR-T therapies for leukemia and lymphoma.
Currently, most CAR-T products for multiple myeloma focus on the BCMA target. While other targets, such as GPRC5D, are under investigation, BCMA-targeted therapies have demonstrated superior results, with response rates reaching 90% to 100%. Although clinical trials are ongoing for different targets, early treatment with BCMA-targeted CAR-T is recommended to maximize benefits.
Begin your CAR-T treatment journey in China
Choosing CAR-T therapy is an important medical decision that requires expert evaluation and individualized planning. Every patient’s disease history is unique, and the most appropriate treatment approach depends on previous therapies, current health, and treatment goals.
If you are considering CAR-T cell therapy for multiple myeloma, our medical team can review your records, discuss available treatment options, and help determine whether treatment in China may be appropriate for your situation.